髋关节置换术后应用利伐沙班预防下肢深静脉血栓的疗效与安全性研究

Study on the efficacy and safety of rivaroxaban in preventing deep vein thrombosis of lower limbs after hip replacement

目的评价髋关节置换术后应用利伐沙班预防下肢深静脉血栓的疗效与安全性。方法60例行髋关节置换术患者,随机分为观察组和对照组,各30例。观察组给予利伐沙班治疗,对照组给予低分子肝素治疗。比较两组下肢深静脉血栓发生率、不良反应发生率、用药满意度及治疗前后血小板及凝血指标。结果观察组下肢深静脉血栓发生率为10.00%,低于对照组的33.33%,差异具有统计学意义(P<0.05)。治疗前,两组血小板及活化部分凝血活酶时间(APTT)比较,差异无统计学意义(P>0.05);治疗后,观察组血小板及APTT均优于对照组,差异具有统计学意义(P<0.05)。观察组用药满意度96.67%高于对照组的76.67%,差异具有统计学意义(P<0.05)。观察组不良反应发生率为6.67%,低于对照组的26.67%,差异具有统计学意义(P<0.05)。结论髋关节置换术后使用利伐沙班,其发生下肢深静脉血栓的几率明显下降,且安全性较高,患者接受度较好。

Objective To evaluate the efficacy and safety of rivaroxaban in preventing deep vein thrombosis of lower limbs after hip replacement.Methods A total of 60 patients undergoing hip replacement were randomly divided into observation group and control group,with 30 cases in each group.The observation group was treated with rivaroxaban,and the control group was treated with low-molecular-weight heparin.The incidence of deep vein thrombosis,adverse reactions,medication satisfaction,platelet and coagulation indexes before and after treatment were compared between the two groups.Results The incidence of deep vein thrombosis in the observation group was 10.00%,which was lower than 33.33% in the control group,and the difference was statistically significant(P<0.05).Before treatment,there was no statistically significant difference between the two groups of platelets and activated partial thromboplastin time(APTT)(P>0.05).After treatment,the platelets and APTT of the observation group were better than those of the control group,and the difference was statistically significant(P<0.05).The medication satisfaction 96.67% of the observation group was higher than 76.67% of the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions in the observation group was 6.67%,which was lower than 26.67% in the control group,and the difference was statistically significant(P<0.05).Conclusion The use of rivaroxaban after hip replacement can significantly reduce the incidence of deep vein thrombosis,and is safer and better accepted by patients.